Search

for
Search:

Research

5 / 1000+ results

research Discovery of a Novel Non-invasive AR PROTAC Degrader for the Topical Treatment of Androgenetic Alopecia

December 2024 in “Journal of Medicinal Chemistry”

In this study, researchers discovered a compound called C6 that exhibits excellent skin retention and androgen receptor degradation properties, significantly promoting hair regeneration in a mouse model of androgenetic alopecia following non-invasive topical application, suggesting potential for broader use of PROTACs in treating skin diseases.

Protac Degraders of Androgen Receptor-Integrated Dissolving Microneedles for Androgenetic Alopecia and Recrudescence Treatment via Single Topical Administration

research PROTAC Degraders of Androgen Receptor‐Integrated Dissolving Microneedles for Androgenetic Alopecia and Recrudescence Treatment via Single Topical Administration

December 2022 in “Small methods”

This study developed dissolving microneedles incorporating a new AR degrader for treating androgenetic alopecia, showing that a single application leads to superior hair regeneration compared to daily minoxidil, without systemic toxicity or androgen-related issues.

research Discovery of an Androgen Receptor Degrader Featuring a Pyridazinyl Glutarimide CRBN-Binding Motif for Transdermal Treatment of Androgenetic Alopecia

May 2026 in “Journal of Medicinal Chemistry”

In this study, the authors developed a novel PROTAC named dAR-6–1, which demonstrated superior hair regeneration in an AGA mouse model compared to minoxidil, highlighting its promise as a therapy due to potent AR degradation and excellent skin permeability.

research Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer

February 2024 in “Cancers”

This review highlights recent progress in developing androgen receptor degraders, such as PROTACs, for treating castration-resistant prostate cancer, and notes that several have entered phase I or II clinical trials, showcasing potential to address drug resistance challenges.

research Expanding the Scope of PROTACs: Opportunities and Challenges in Topical Delivery

November 2025 in “Journal of Medicinal Chemistry”

This review outlines advances in topical PROTACs for localized protein degradation, focusing on AH-001 and GT20029 for skin conditions, but presents no new clinical trial results.

View more "protac ar degraders" in research →

Community Join

5 / 35 results

community AH-001 another topical AR degrader beside GT20029, completed Phase I

8 upvotes 10 months ago

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

community Androgen degraders for hair loss

61 upvotes 2 years ago

The conversation discusses androgen receptor degraders for hair loss, highlighting their potential advantages over traditional AR blockers like RU58841 and pyrilutamide. Concerns about the safety and cost of these treatments are also mentioned.

community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

133 upvotes 2 years ago

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

community Most Promising Future Hair Loss Treatments In 2026

83 upvotes 2 days ago

Promising hair loss treatments in 2026 include GT20029, a topical androgen receptor degrader, and VDPHL01, an extended-release oral minoxidil, both offering safer alternatives with fewer side effects. Other treatments like sublingual minoxidil, OND-1, JW0061, TDM-105795, and AMP-303 are also being explored.

community IGFBP‐rP1 is a potential therapeutic target in androgenic alopecia

in Research/Science 13 upvotes 1 year ago

IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.

View more "protac ar degraders" in community →